NCT04997850
- Conditions
- Hepatocellular Carcinoma Non-resectable, Immune Checkpoint Blockade, Transarterial Chemoembolization, +1 more
- Locations
-
- West China Hospital of Sichuan University Chengdu, Sichuan, China
Clinical trial condition
Tyrosine Kinase Inhibitor
Explore clinical trials studying Tyrosine Kinase Inhibitor. Study availability and eligibility vary by location and protocol.
15 public trials
5 recruiting studies
Tyrosine Kinase Inhibitor trial results
NCT03996096
- Conditions
- Bone Marrow Diseases, Chemically-Induced Disorders, Chronic Disease, +17 more
- Locations
-
- University hospital Caen, France
Completed
Oncotool for Cancer Medications
NCT03952312
- Conditions
- Behavior, Cancer, Cancer, Treatment-Related, +9 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
Active, Not Recruiting
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- The first hospital of China medical university Shenyang, Liaoning, China
Active, Not Recruiting
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166
- Conditions
- Adnexal Diseases, Angiogenesis, Anlotinib, +22 more
- Locations
-
- Huai'an First People's Hospital Huai'an, China
- Nanjing Drum Tower Hospital Nanjing, China
- Zhongda Hospital Southeast University Nanjing, China
- The First Affiliated Hospital of Soochow University Suzhou, China